Anna C. Cole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna C. Cole has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Chrystal M. Paulos
Winship Cancer Institute, Emory University
35 shared publications - Gregory B. Lesinski
Emory University
33 shared publications - Megan M. Wyatt
Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia
32 shared publications - Aubrey S. Smith
Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia
31 shared publications - Soundharya Kumaresan
Department of Surgery, Winship Cancer Institute of Emory University, Atlanta, Georgia
31 shared publications - Megen C. Wittling
Department of Surgery, Emory University, Atlanta, Georgia, USA
27 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance:B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance:B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CpG conditioning by distinct CpG classes on pmel-1 CD8 increases T cell activation and cytokine production
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CpG conditioning by distinct CpG classes on pmel-1 CD8 increases T cell activation and cytokine production
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD28 or Icos blocking does not impair CpG conditioned CD8 T cells
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD28 or Icos blocking does not impair CpG conditioned CD8 T cells
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 signaling is required for TLR9 driven B cell differentiation
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 signaling is required for TLR9 driven B cell differentiation
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Metabolic profiling of B cells and CD8 T cells following CpG conditioning and CD2 blockade
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Metabolic profiling of B cells and CD8 T cells following CpG conditioning and CD2 blockade
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Flow cytometry and blocking antibody list
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Flow cytometry and blocking antibody list
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
TLR9-activated B cell interactions with human CD8 T cells may limit their exhaustion
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
TLR9-activated B cell interactions with human CD8 T cells may limit their exhaustion
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 and CD58 expression is increased in intratumoral human B and T cells
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
CD2 and CD58 expression is increased in intratumoral human B and T cells
- Open Access
- 6 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (19) , 4840-4855
TLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance: B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
- 6 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (19) , 4840-4855
Open AccessTLR9 Agonists Potentiate Adoptive T-cell Therapy in Cancer through a B-cell–CD2 Costimulatory Axis
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate–adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell–CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. Significance: B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 9 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 9: Viability (A) Representative flow plots showing viability of cells in the lymph node of mice given FTY720 or no treatment. Gated on Lymphocytes/Single Cells. (B) Bar graph of viability for all samples. Mann Whitney test performed (p=0.5476).
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 9 from T-cell Priming by High-Avidity Neoantigens in Lymph Nodes Augments Adoptive Immunotherapy
Supplemental Figure 9: Viability (A) Representative flow plots showing viability of cells in the lymph node of mice given FTY720 or no treatment. Gated on Lymphocytes/Single Cells. (B) Bar graph of viability for all samples. Mann Whitney test performed (p=0.5476).